

**FORM 13-502F1**  
**CLASS 1 AND CLASS 3B REPORTING ISSUERS – PARTICIPATION FEE**

**MANAGEMENT CERTIFICATION**

I, Blake Sing, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the **Form**) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

(s) "Blake Sing"  
Name: Blake Sing  
Title: Chief Financial Officer

January 25, 2022  
Date:

**Reporting Issuer Name:** Nurosene Health Inc.

**End date of previous financial year:** September 30, 2021

**Type of Reporting Issuer:**  **Class 1 reporting issuer**  **Class 3B reporting issuer**

**Highest Trading Marketplace:** Canadian Securities Exchange (CSE)  
(refer to the definition of "highest trading marketplace" under OSC Rule 13-502 Fees)

**Market value of listed or quoted equity securities:**  
(in Canadian Dollars - refer to section 7.1 of OSC Rule 13-502 Fees)

**Equity Symbol** MEND

**1<sup>st</sup> Specified Trading Period (dd/mm/yy)**  
(refer to the definition of "specified trading period" under OSC Rule 13-502 Fees)

07/06/21 to 30/06/21

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace \$ 2.54 (i)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period 33,221,078 (ii)

Market value of class or series (i) x (ii) \$ 84,381,538 (A)

**2<sup>nd</sup> Specified Trading Period (dd/mm/yy)**  
(refer to the definition of "specified trading period" under OSC Rule 13-502 Fees)

01/07/21 to 30/09/21

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace \$ 1.67 (iii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period 33,771,611 (iv)

Market value of class or series (iii) x (iv) \$ 56,398,590 (B)

**3<sup>rd</sup> Specified Trading Period** (dd/mm/yy)

(refer to the definition of “specified trading period” under OSC Rule 13-502 Fees)

N/A\* to N/A\*

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ N/A (v)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

N/A (vi)

Market value of class or series

(v) x (vi) \$ \_\_\_\_\_ (C)

**4<sup>th</sup> Specified Trading Period** (dd/mm/yy)

(refer to the definition of “specified trading period” under OSC Rule 13-502 Fees)

N/A\* to N/A\*

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ N/A (vii)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

N/A (viii)

Market value of class or series

(vii) x (viii) \$ N/A (D)

**5<sup>th</sup> Specified Trading Period** (dd/mm/yy)

(if applicable, refer to the definition of “specified trading period” under OSC Rule 13-502 Fees)

N/A\* to N/A\*

Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace

\$ N/A (ix)

Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period

N/A (x)

Market value of class or series

(ix) x (x) \$ N/A (E)

**Average Market Value of Class or Series**

(Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))

\$ 70,390,064 (1)

\*Nurosene Health Inc. commenced trading on the Canadian Securities Exchange on June 9, 2021 and did not trade on any other stock exchange Canadian or otherwise prior to such date. As such, trading data is only available for Nurosene Health Inc. starting June 9, 2021 through to September 30, 2021 for the previous financial year.

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary pursuant to paragraph 2.8(1)(c) of OSC Rule 13-502 *Fees*, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

**Fair value of outstanding debt securities:**

(See paragraph 2.8(1)(b), and if applicable, paragraph 2.8(1)(c) of OSC Rule 13-502 *Fees*)

\$ 0 (2)

(Provide details of how value was determined)

**Capitalization for the previous financial year**

(1) + (2) \$ 70,390,064

**Participation Fee**

(For Class 1 reporting issuers, from Appendix A of OSC Rule 13-502 *Fees*, select the participation fee)

\$ 6,390

(For Class 3B reporting issuers, from Appendix A.1 of OSC Rule 13-502 *Fees*, select the participation fee)

**Late Fee, if applicable**

(As determined under section 2.7 of OSC Rule 13-502 *Fees*)

\$ N/A

**Total Fee Payable**

(Participation Fee plus Late Fee)

\$ 6,390